Herbal Drugs: USP introduces Acceptance Criteria for PAHs
Recommendation

20/21 October 2026
Understanding the Importance of GMP
Following the draft version published last year, the USP now introduced testing on Polycyclic aromatic hydrocarbons (PAHs) in the gereral chapter <561> Articles of Botanical Origin (ABOs). The chapter will become official on 1 December 2026.
Analytical Procedure and Acceptance Criteria
Polycyclic aromatic hydrocarbons (PAHs) are carbon- and hydrogen-based compounds with two or more fused aromatic rings. Some PAHs, including benzo[a]pyrene, are genotoxic and carcinogenic. Medicinal plants may become contaminated through environmental exposure or post-harvest processing, particularly drying.
The analytical procedure for PAH detection is based on Gas Chromatography (GC) coupled with Mass spectrometry (quadrupole time-of-flight, Q-TOF) (GC-MS) using Electron impact (EI+) as onization mode. The acceptance criteria are the following:
- Benzo[a]pyrene: max. 10.0 ppb
- Sum of benzo[a]pyrene, chrysene, benz[a]anthracene, and benzo[b]fluoranthene: max. 50.0 ppb
More information is available in the USP chapter <561> Articles of Botanical Origin.
Related GMP News
29.09.2026FDA wants to Advance the Development of Herbal Medicinal Products
29.09.2026Ph. Eur. Draft for Comment: 2.8.18. Determination of Aflatoxin B1 in Herbal Drugs
29.09.2026Can Cannabis Flowers be pre-dried in Accordance with GACP?
29.09.2026Water Determination in Herbal Drugs
10.09.2026New Information Sheet regarding Cannabis for Medical Purposes
10.09.2026EMA Reflection Paper on Safety Signals for Herbal Medicinal Products


